Showing results (1-10 of 64) with videos related to
Sort By:
Pageof 7
Journal of Controlled Release : Official Journal of the Controlled Release Society|December 3, 2014
A photosensitizer delivered by bispecific antibody redirected T lymphocytes enhances cytotoxicity against EpCAM-expressing carcinoma cells upon light irradiationAndré-René Blaudszun, Gerhard Moldenhauer, Marc Schneider, et al.Journal of Immunological Methods|May 14, 2015
A novel method for measuring cellular antibody uptake using imaging flow cytometry reveals distinct uptake rates for two different monoclonal antibodies targeting L1John Hazin, Gerhard Moldenhauer, Peter Altevogt, et al.International Journal of Cancer|September 5, 2002
Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinomaAlexander Marmé, Gudrun Strauss, Gunther Bastert, et al.Journal of Immunological Methods|February 12, 2004
Immunosuppressive properties of anti-CD3 single-chain Fv and diabodyFabrice Le Gall, Uwe Reusch, Gerhard Moldenhauer, et al.Oncoimmunology|August 31, 2012
Combining forces to hit cancer stem cells: TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody show efficacy against pancreatic cancerIngrid Herr, Ariane Groth, Alexei V Salnikov, et al.Immunology Letters|March 6, 2012
Detection of circulating tumor-associated antigen depends on the domains recognized by the monoclonal antibodies used: N-terminal trimmed EpCAM-levels are much higher than untrimmed formsOliver Schmetzer, Gerhard Moldenhauer, Annett Nicolaou, et al.International Journal of Cancer|July 17, 2010
Functional analysis of bispecific antibody (EpCAMxCD3)-mediated T-lymphocyte and cancer cell interaction by single-cell force spectroscopySabrina C Hoffmann, Guido H Wabnitz, Yvonne Samstag, et al.Human Pathology|July 27, 2006
Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapyMonica Huszar, Gerhard Moldenhauer, Verena Gschwend, et al.Cancer Immunology, Immunotherapy : CII|November 20, 2002
Efficient carcinoma cell killing by activated polymorphonuclear neutrophils targeted with an Ep-CAMxCD64 (HEA125x197) bispecific antibodyChristof Schweizer, Gudrun Strauss, Matthias Lindner, et al.Journal of Immunology (Baltimore, Md. : 1950)|January 7, 2005
Quality of recombinant protein determines the amount of autoreactivity detected against the tumor-associated epithelial cell adhesion molecule antigen: low frequency of antibodies against the natural proteinOliver Schmetzer, Gerhard Moldenhauer, Rainer Riesenberg, et al.Pageof 7